Finding. Procyanidin C1, at a senomorphic/senolytic dose, rewrites thousands of genes in bleomycin-senescent human stromal cells. Ribosomes move first. Lysosomes next. Lipid-transport programs that senescence had turned down come back. Mitochondrial-membrane, lysosomal-membrane, cholesterol, and ion-transport programs, already up in senescence, go up again. A tight SASP-effector score falls. A broad SASP gene set does not survive false-discovery correction. The organelle is present as a membrane-ontology trajectory.
Why this paper matters
PCC1 already had a reputation as a grape-seed senotherapeutic. What it did to the transcriptome, in a replicate-controlled contrast, was fuzzy. This reanalysis gives a shape: infrastructure (ribosomes, lysosomes, membranes) more than a clean SASP wipe.
The mitochondrial reason to keep it is modest and should stay modest. Mitochondrial-membrane genes travel with lysosomal-membrane and cholesterol genes, up in senescence and up again with drug. That could be remodeling, stress, or both. It is not a rescue claim.
What they actually measured
Published RNA-seq counts, three replicates, 50 µM PCC1 on bleomycin-senescent PSC27. 8,420 DE genes. Ontology structure as above. Prespecified SASP-effector down; Reactome SASP not significant. AP-1 shift; HSP90/HSF1/proteostasis up.
How to read the score
High sixties. Honest reanalysis, thin mitochondrial mechanism. Score 68.
What to do with it
If you follow senomorphics or stromal SASP, pull the ribosomal and membrane-lipid gene sets. If you need a mitochondrial phenotype, measure one; this paper did not. The directional implication is that PCC1 remakes senescent-cell infrastructure, including mitochondrial-membrane transcripts, more cleanly than it erases SASP.